Connexion
M'inscrire

Votre recherche

Filtres

Project précédent
Projet suivant
Nous verifions auprès de chaque centre si des nouvelles informations sont disponibles

0306381

Vonoprazan for helicobacter pylori eradication in adolescents
Source : Importé depuis le centre

Référence clinicaltrials.gov: NCT06162949
Helicobacter pylori
Vonoprazan
Standard triple therapy
Adolescent
Eradication rate
Source : Importé depuis le centre
Recrutement fermé
Dernière modification : 2024/08/27
Type de recherche

Interventionnel

Médicament expérimental

PHASE3


Population cible

Condition médicale (spécialité visée)

Donnée non disponible

Profil des participants

Sexe(s) des participants

ALL

Source : Importé depuis le centre

Critères de sélection

Critères d'inclusion

Inclusion Criteria:

1. Children in the age group (10-18 years), both genders, referred with dyspeptic complaints such as heartburn, dyspepsia, nausea, and epigastric pain.
2. Who is positive for H. Pylori infection by a standardized diagnostic test.
3. Pediatric patients with a clinical, laboratory, and endoscopic diagnosis of H.P.-positive gastritis and the other conditions necessary for H.P. eradication according to the Maastricht V consensus report.

Exclusion Criteria:

1. allergy to any of the drugs used in the study
2. previous attempts to eradicate H.P.
3. Use of antibiotics, acid-suppression, bismuth, or probiotics 4 weeks before enrollment.
4. Children with conditions that affect medication absorption e.g. celiac or Crohn's disease.
5. Liver or kidney failure.
6. symptoms suggestive of functional disorders.

Source : Importé depuis le centre

Thérapie ou Intervention proposée

Cohortes
Nom Condition médicale Traitement État du recrutement
Vonoprazan-based triple therapy Vonoprazan tablets 20 mg twice daily plus Amoxicillin 50 mg/kg/day capsules or suspension \[maximum daily dose 2 g\] plus Clarithromycin 20 mg/kg/day tablets or suspension \[maximum daily dose 1 g\] The triple combination will be given for 14 days Donnée non disponible
  • Inconnu
  • Proton pump-based triple therapy "standard triple therapy" Esomeprazole tablets \[20 mg/day if \< 30 kg and 40 mg/daily if ≥ 30 kg\] on two divided daily doses plus Amoxicillin 50 mg/kg/day capsules or suspension \[maximum daily dose 2 g\] plus Clarithromycin 20 mg/kg/day tablets or suspension \[maximum daily dose 1 g\] The triple combination will be given for 14 days Donnée non disponible
  • Inconnu
  • Vonoprazan-based triple therapy
    État du recrutement
    unknown
    Proton pump-based triple therapy "standard triple therapy"
    État du recrutement
    unknown
    Données à jour depuis : 27 août 2024

    Description de l'étude

    Résumé de l'étude

    The trial tends to evaluate the efficacy of vonoprazan-based triple therapy in eradicating H. Pylori infection in adolescent patients in Egypt, in comparison to standard treatment regimens to determine if it offers superior eradication rates (VONTAPE trial).

    Source : Importé depuis le centre

    The VONTAPE trial will compare two treatment regimens for Helicobacter pylori eradication among adolescent patients presented to the gastroenterology department in an Egyptian institute. the eligible subjects will be randomly assigned to one of the two protocols (vonoprazan based vs. proton pump inhibitor-based triple therapy) for two weeks. then the eradication rates will be compared between the two study groups to see if there is a difference in efficacy.

    The currently available eradication regimens in our country show a low to intermediate eradication rate (50-75%). At the same time, H. pylori infection is prevalent.

    Recently, the FDA approved vonoprazan-based regimens for adult H. pylori infection with high eradication rates even in the settings of clarithromycin antibiotic resistance.

    In the VOTSAPE trial, we will test this efficacy in the \< 18 years adolescents.

    Source : Importé depuis le centre

    Sites

    Centres participants

      1 centres
    • ALEXANDRIA CLINICAL RESEARCH CENTER, FACULTY OF MEDICINE

      Alexandria

      GHARBIA, EGYPT

      Recrutement local
      État du recrutement: FERMÉ

    Dernière modification : 27 août 2024
    Données à jour depuis : 29 août
    Origine des données : clinicaltrials.gov
    Référence clinicaltrials.gov: NCT06162949